All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
171 results
Alliance A041501: A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to front-line therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-cell ALL
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Protocol No
ALLIANCE-A041501
Sub Category
Hematologic/Blood Related Cancers
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in CML Patients with Molecular Evidence of Disease
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
Protocol No
SWOG-S1712
Sub Category
Hematologic/Blood Related Cancers
Alliance A041703: A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive B-lineage ALL in newly diagnosed older adults or adults with relapsed or refractory disease
Inotuzumab Ozogamicin & Blinatumomab in Patients w/ Newly Diagnosed, Recurrent, or Refractory ALL
Protocol No
ALLIANCE-A041703-ALL
Sub Category
Hematologic/Blood Related Cancers
Phase 2 Trial of Intensive Chemo-immunotherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation
A study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for patients with relapsed refractory Multiple Myeloma in the context of an autologous hematopoietic stem cell transplant
Protocol No
MSKCC-17-493
Sub Category
Hematologic/Blood Related Cancers
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine the Efficacy and Safety of bb2121 in subjects with Relapsed and Refractory Multiple Myeloma and in subjects with high-Risk Multiple myeloma having Progressed Within One Year of Initial Treatment (KarMMa-2)
An Efficacy and Safety Study of bb2121 in Subjects with rrMM and in Subjects with High-risk MM
Protocol No
CELGENE-BB2121-MM-002-KARMMA2
Sub Category
Hematologic/Blood Related Cancers
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Cancer
SBRT +/- Pembrolizumab in Patients w/ Local-Regionally Recurrent or 2nd Primary Head and Neck Cancer
Protocol No
RTOG-3507
Sub Category
Head and Neck Cancers
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
Protocol No
IOVANCE-IOV-COM-202
Sub Category
Head and Neck Cancers
Thoracic Cancers
Skin Cancers
Monoclonal Antibody-Based Sequential Therapy For Deep Remission In Multiple Myeloma MASTER TRIAL
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)
Protocol No
UAB-1735-MASTER
Sub Category
Hematologic/Blood Related Cancers
Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The objective is to evaluate safety and compare progression free survival between subjects receiving neoadjuvant chemotherapy (NACT) plus GEN-1 versus NACT alone
Protocol No
CELSION-201-17-201
Sub Category
Gynecologic Cancers
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A Phase 2 Randomized Multicenter Trial to Compare Hepatic Progression-free Survival Following Bland Embolization, Lipiodol Chemoembolization, and Drug-eluting Bead Chemoembolization of Neuroendocrine Liver Metastases
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
Protocol No
U-PENN-UPCC-01215-RETNET
Sub Category
Gastrointestinal Cancers
A Phase 1B/2 Study to Evaluate the safety, Tolerability, Phamacokinetics, Phamacodynamics, and Clinical Activity or EQ001 In Subjects with Newly Diagnosed Acute Graft Versus Host Disease
A Study to Evaluate the Safety, Tolerability, PK, PD of EQ001 in subjects with aGVHD
Protocol No
EQUILLIUM-EQ001-AGVHD
Sub Category
Hematologic/Blood Related Cancers
An Open Label, Non-Randomized Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
To see combining three drugs, Bevacizumab, Atezolizumab and Rucaparib works well for previously treated recurrent Endometrial Cancer.
Protocol No
IIT-BRADLEY-ENDOBARR
Sub Category
Gynecologic Cancers
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adults Patients With Progressing Desmoid Tumors (DTs) Aggressive Fibromatosis (AF)
Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Protocol No
SPRINGWORKS-NIR-DT-301
Sub Category
Sarcoma
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Standard Systemic Therapy +/- Definitive Treatment in Treating Metastatic Prostate Cancer
Protocol No
SWOG-S1802
Sub Category
Prostate and Urologic Cancers
A Phase I Study of Lintuzumab-Ac225 in Patients with Refractory Multiple Myeloma
Lintuzumab-Ac225 is an investigational drug for the treatment of multiple myeloma (MM). It is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)]. CD33 is a surface protein seen in a subset of malignant plasmocytes, which are the cancerous cells in multiple myeloma. Anti-CD 33 antibody joined together with the radioactive isotope will selectively bind to CD33 surface proteins and may deliver more radiation to your bone marrow and sometimes spleen and liver, where most myeloma cells are present, compared to other organs such as lungs, kidneys and mucous membranes.
This is a phase I trial. The purpose of the study is to observe the safety, efficacy (good or bad) and determine the maximum dose of Lintuzumab-Ac225 that can be given to patients with multiple myeloma like you without causing bad effects.
This is a phase I trial. The purpose of the study is to observe the safety, efficacy (good or bad) and determine the maximum dose of Lintuzumab-Ac225 that can be given to patients with multiple myeloma like you without causing bad effects.
Protocol No
ACTINIUM-LIN-AC225-MM01
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers